


## Dictyostatin

<b>Cat. No.:</b>	HY-N10660
<b>CAS No.:</b>	156312-07-1
<b>Molecular Formula:</b>	C <sub>32</sub> H <sub>52</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	532.75
<b>Target:</b>	Microtubule/Tubulin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Dictyostatin ((-)-Dictyostatin; Dictyostatin 1) is a potent microtubule stabilizing agent. Dictyostatin also is a anti-cancer agent. Dictyostatin shows antiproliferative activity. Dictyostatin has the potential for the research of tauopathies <sup>[1][2][3]</sup> .								
<b>In Vitro</b>	<p>Dictyostatin (0-100 nM; 72-120 h) shows antiproliferative activity in cancer cells<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549, EpoB40/A549, 1A9, 1A9/PTX10, 1A9/PTX22 cells</td> </tr> <tr> <td>Concentration:</td> <td>0-100 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>72-120 h</td> </tr> <tr> <td>Result:</td> <td>Showed antiproliferative activity with GI<sub>50</sub>s of 0.5, 5.1, 1.3, 18.8, 5.1 nM for A549, EpoB40/A549, 1A9, 1A9/PTX10, 1A9/PTX22 cells, respectively.</td> </tr> </table>	Cell Line:	A549, EpoB40/A549, 1A9, 1A9/PTX10, 1A9/PTX22 cells	Concentration:	0-100 nM	Incubation Time:	72-120 h	Result:	Showed antiproliferative activity with GI <sub>50</sub> s of 0.5, 5.1, 1.3, 18.8, 5.1 nM for A549, EpoB40/A549, 1A9, 1A9/PTX10, 1A9/PTX22 cells, respectively.
Cell Line:	A549, EpoB40/A549, 1A9, 1A9/PTX10, 1A9/PTX22 cells								
Concentration:	0-100 nM								
Incubation Time:	72-120 h								
Result:	Showed antiproliferative activity with GI <sub>50</sub> s of 0.5, 5.1, 1.3, 18.8, 5.1 nM for A549, EpoB40/A549, 1A9, 1A9/PTX10, 1A9/PTX22 cells, respectively.								
<b>In Vivo</b>	<p>Dictyostatin (0.3, 1 mg/kg; i.p.; once-weekly for 3 months) improves MT density and reduced axonal dystrophy in mouse<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>6-month old male B6 PS19 tau Tg mice<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; once-weekly for 3 months</td> </tr> <tr> <td>Result:</td> <td>Improved MT density and reduced axonal dystrophy, with a reduction of tau pathology and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice, caused a significant reduction of insoluble TauAck280.</td> </tr> </table>	Animal Model:	6-month old male B6 PS19 tau Tg mice <sup>[3]</sup>	Dosage:	0.3, 1 mg/kg	Administration:	i.p.; once-weekly for 3 months	Result:	Improved MT density and reduced axonal dystrophy, with a reduction of tau pathology and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice, caused a significant reduction of insoluble TauAck280.
Animal Model:	6-month old male B6 PS19 tau Tg mice <sup>[3]</sup>								
Dosage:	0.3, 1 mg/kg								
Administration:	i.p.; once-weekly for 3 months								
Result:	Improved MT density and reduced axonal dystrophy, with a reduction of tau pathology and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice, caused a significant reduction of insoluble TauAck280.								

### REFERENCES

[1]. George R. Pettit, et al. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. J. Chem. Soc., Chem. Commun., 1995, 2373-2670.

---

[2]. Vollmer LL, et al. A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos. *Mol Cancer Ther.* 2011 Jun;10(6):994-1006.

[3]. Makani V, et al. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. *Acta Neuropathol Commun.* 2016 Sep 29;4(1):106.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA